BioSpace News Archive

Altamira Therapeutics Ltd. today announced that it has entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG (“Medica”) to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology.

Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.

Genome Insight will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

The National Eczema Association (NEA) announces the publication of new research on the burden of prescription treatments for comorbid conditions for patients with atopic dermatitis (AD).

FORE Biotherapeutics reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib, a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.

CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma with the recommended Phase 2 dose of ivaltinostat.

Arecor Therapeutics plc, the biopharmaceutical company advancing ’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220, incorporating its proprietary Arestat™ technology platform.

Medicenna Therapeutics Corp. announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp, the Company’s first-in-class IL-4R targeted therapy for the treatment of patients with recurrent glioblastoma, will be presented by Dr. Steven Brem, M.D. at the Society for Neuro-Oncology 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada.

BrainStorm Cell Therapeutics Inc. today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE.